Spectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication
Spectral AI, Inc. (Nasdaq: MDAI) appointed Darcy Bajko as Chief Commercial Officer effective July 31, 2026, to lead global sales for its FDA De Novo-cleared DeepView System for burn indication. The company said it aims to close its first commercial sales by year end 2026 and target adoption in US burn centers and emergency departments.
How this was made
The 30-second read
Why it matters
The appointment is positioned as a step-change from product development to commercial execution, with an explicit near-term objective to close first commercial sales by year-end 2026.
Market read
Investors get a concrete commercialization milestone narrative (CCO appointment tied to FDA-cleared product launch) but no new financial metrics.
What to watch
The release lacks details on pricing, reimbursement status, distribution partners, and current pipeline conversion, which are key drivers of whether the year-end sales target is credible.
Background
Spectral AI’s DeepView System received FDA De Novo classification in May 2026 for burn indication, and this release adds a CCO to lead the global sales launch.
Ticker impact
Spectral AI appointed Darcy Bajko as CCO to lead global sales for its FDA De Novo-cleared DeepView burn indication system.
Moderate upside bias for MDAI on execution optimism, with follow-through dependent on reported commercial sales traction.
The article is a primary company announcement (exec appointment tied to a specific FDA-cleared product launch) but provides no financial guidance or sales numbers, limiting immediate magnitude.
Market effects
Highlights commercialization momentum for AI-enabled medical diagnostics in wound care, potentially supporting sentiment toward similar med-tech AI platforms.
Primarily US-focused adoption narrative (burn centers and emergency departments).
Frames a global launch, which could broaden investor interest beyond the US if international adoption timelines emerge.
Counterpoint
An executive appointment alone may not change fundamentals until measurable commercial adoption, reimbursement traction, and sales ramp are reported.
Key entities
- companySpectral AI, Inc.
Nasdaq-listed AI medical diagnostics company launching DeepView for burn indication after FDA De Novo clearance.
- executiveDarcy Bajko
Appointed Chief Commercial Officer effective July 31, 2026 to lead global sales for DeepView.
- productDeepView System
Non-invasive predictive AI diagnostic for burn wound healing potential, cleared via FDA De Novo in May 2026.
